uniQureQURE
Market Cap: $264M
About: uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
Employees: 480
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
149% more call options, than puts
Call options by funds: $7.81M | Put options by funds: $3.14M
0.2% more ownership
Funds ownership: 70.61% [Q1] → 70.81% (+0.2%) [Q2]
3% less repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 37
10% less funds holding
Funds holding: 129 [Q1] → 116 (-13) [Q2]
14% less capital invested
Capital invested by funds: $178M [Q1] → $154M (-$24.3M) [Q2]
41% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 32
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
HC Wainwright & Co. Patrick Trucchio 30% 1-year accuracy 40 / 135 met price target | 361%upside $25 | Buy Reiterated | 20 Aug 2024 |
Goldman Sachs Salveen Richter 50% 1-year accuracy 10 / 20 met price target | 85%upside $10 | Neutral Maintained | 2 Aug 2024 |
Cantor Fitzgerald Kristen Kluska 59% 1-year accuracy 48 / 81 met price target | 343%upside $24 | Overweight Reiterated | 16 Jul 2024 |
HC Wainwright & Co. Patrick Trucchio 30% 1-year accuracy 40 / 135 met price target | 361%upside $25 | Buy Reiterated | 9 Jul 2024 |